| Funding Opportunity ID: |
318959 |
| Opportunity Number: |
RFA-HD-20-007 |
| Opportunity Title: |
The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health
Income Security and Social Services |
| Category Explanation: |
|
| CFDA Number(s): |
93.865 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Jul 30, 2019 |
| Close Date: |
Sep 03, 2019 |
| Last Updated Date: |
Jul 30, 2019 |
| Award Ceiling: |
$200,000 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
$1,600,000 |
| Expected Number of Awards: |
|
| Description: |
The primary focus of this FOA is to promote studies which apply state-of-the art concepts, technologies, and methodologies in the stem cell field to better understand how stem cells function within diseased or damaged gynecologic tissues. For the purposes of this announcement, the gynecologic disorders of interest are limited to uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. These disorders have been chosen based on their prevalence, high associated morbidity, high branch priority, and substantial costs to the healthcare system. The ultimate goal of this initiative is to improve womens gynecologic health by accelerating our understanding of the role of pluripotent progenitor/stem cells in the initiation, progression and severity of these gynecologic disorders in order to inform the development of effective prevention, diagnostic, and therapeutic strategies. |
| Version: |
1 |
|
